“As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested.”
Credit: © 2024 Miranda-Carboni and Krum.
“As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested.”
BUFFALO, NY- September 4, 2024 – A new review was published in Oncotarget‘s Volume 15 on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.”
As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation. There is, however, controversy in the field of osteosarcoma as to whether WNT signaling is pro- or anti-tumorigenic. WNT5B, a β-catenin-independent ligand, and WNT10B, a β-catenin-dependent WNT ligand, are each expressed in osteosarcomas, but they are not expressed in the same tumors.
In this review, researchers Gustavo A. Miranda-Carboni and Susan A. Krum from the University of Tennessee Health Science Center in Memphis, identified key osteoblast differentiation genes (SP7 (osterix), ALPL, BMP4, and PHOSPHO1) through RNA-sequencing of osteosarcoma patient tumors. They found that WNT10B correlated positively with these genes, whereas WNT5B showed an inverse correlation.
“As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested.”
Correspondence to: Susan A. Krum – smirand5@uthsc.edu
Keywords: cancer, WNT5B, WNT10B, WNT signaling, osteosarcoma
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
Journal
Oncotarget
Method of Research
News article
Subject of Research
Not applicable
Article Title
Targeting WNT5B and WNT10B in osteosarcoma
Article Publication Date
2-Aug-2024
COI Statement
Authors have no conflicts of interest to declare.
